Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1 4Phase 3 1

Status

Completed 4Withdrawn 2

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Gastrointestinal 1CNS 1

Conditions

Small Cell Lung Carcinoma 1Sarcoma 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Glioblastoma 1Brain Neoplasms 1

Interventions

Cyclophosphamide 741Cisplatin 688Gemcitabine 641Bevacizumab 616Carboplatin 605Paclitaxel 601Docetaxel 565Radiotherapy 536Fluorouracil 405Oxaliplatin 387Rituximab 369Doxorubicin 361Capecitabine 342Filgrastim 333Etoposide 330Dexamethasone 312Irinotecan 309pembrolizumab 280Leucovorin 274Cetuximab 268Cytarabine 242Erlotinib Hydrochloride 231Nivolumab 228Prednisone 227Trastuzumab 225Vincristine 221Bortezomib 221Methotrexate 207Pemetrexed 199fludarabine phosphate 195

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × Completed × DOXO-EMCH × Clear all
NCT02200757 2024-06-25

Efficacy and Safety of Aldoxorubicin Compared to Topotecan in Subjects With Metastatic Small Cell Lung Cancer

ImmunityBio, Inc.

Phase 2 Completed
135 enrolled 11 charts
Thoracic

Small Cell Lung Carcinoma

NCT01580397 2024-06-06

Pilot Phase 2 Study to Investigate the Preliminary Efficacy and Safety of INNO-206 in Advanced Pancreatic Cancer

ImmunityBio, Inc.

Phase 2 Completed
15 enrolled 9 charts
Gastrointestinal

Pancreatic Neoplasms

NCT01514188 2024-05-29

Preliminary Efficacy and Safety of INNO-206 Compared to Doxorubicin in Advanced Soft Tissue Sarcoma

ImmunityBio, Inc.

Phase 2 Completed
126 enrolled 13 charts
Sarcoma

Neoplasm Metastasis, Sarcoma

NCT02014844 2024-05-29

Phase 2 Study to Investigate the Efficacy and Safety of Aldoxorubicin in Subjects With Glioblastoma

ImmunityBio, Inc.

Phase 2 Completed
28 enrolled 10 charts
CNS

Brain Neoplasms, Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡